(Q35198547)

7 August 2017

1 reference

title

Bisphosphonate treatment of osteoporosis (English)

1 reference

7 August 2017

0 references

Nelson B Watts

1

1 reference

7 August 2017

1 May 2003

1 reference

Clinics in geriatric medicine

7 August 2017

1 reference

7 August 2017

19

1 reference

7 August 2017

2

1 reference

7 August 2017

395-414

1 reference

Myositis ossificans progressiva: a 10-year follow-up on a patient treated with etidronate disodium

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Diphosphonates in the treatment of myositis ossificans.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

The effects of etidronate disodium on progressive hearing loss from otosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans)

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Treatment of patients with Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effects of tiludronate on bone loss in paraplegic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Childhood cancer and hypercalcemia: report of a case treated with pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Bisphosphonates for treatment of childhood hypercalcemia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Novel usage of alendronate to prevent profound hypocalcemia immediately after parathyroidectomy in patients with severe secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Bisphosphonates in the treatment of malignant bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Molecular mechanisms of action of bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Pharmacokinetics of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Is Postmenopausal Estrogen Therapy Associated With Neuromuscular Function or Falling in Elderly Women?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

"Pill esophagitis"--the case of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Fatal esophageal perforation with alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Upper gastrointestinal toxicity of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate and naproxen are synergistic for development of gastric ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Etidronate disodium in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Preliminary observations of a form of coherence therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Treatment with etidronate for men with idiopathic osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate)

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Clodronate and osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Intermittent cyclic tiludronate in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Cyclical pamidronate infusions in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Role of oral pamidronate in preventing bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

The acute-phase response after bisphosphonate administration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Side-effects of pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Uveitis associated with pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Pamidronate disodium and possible ocular adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Severe reaction to diphosphonate: implications for treatment of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Pamidronate: an unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Response to alendronate in osteoporosis after previous treatment with etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Effect of alendronate on fracture healing and bone remodeling in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Can bisphosphonates be given to patients with fractures?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Combination therapy for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900069-1

7 January 2021

10.1016/S0749-0690(02)00069-1

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12916293